1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66DFC7B8A24202577852582CF0071E893
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/6DFC7B8A24202577852582CF0071E893!OpenDocument
18
19OpenDocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Data Management and Biostatics

Document Excerpt: Understanding the Changing Landscape of Real World Evidence Generation: Non-Safety Registries

DB Image

Excerpt in Cart

ID: MD-620


Features:

6 Info Graphics

27 Data Graphics

130+ Metrics


Pages/Slides: 4


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt" on the right.


To return to the study abstract to purchase the full study - click here

This excerpt includes research findings and metrics from document #5520 "Understanding the Changing Landscape of Real World Evidence Generation: Non-Safety Registries".


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Bayer; Flexion; Vifor Pharma; Dermira; AstraZeneca; Janssen; EMD Serono; Grifols; GlaxoSmithKline ; Abbott; Novartis; Abbvie; Genzyme; Merck; UCB Pharma; Sanofi; Celldex Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.